




PHARMACEUTICAL 2023

RIGEL PHARMACEUTICALS INC
Rank 343 of 446





PHARMACEUTICAL 2023

RIGEL PHARMACEUTICALS INC

Rank 343 of 446



The relative strengths and weaknesses of RIGEL PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RIGEL PHARMACEUTICALS INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 59% points. The greatest weakness of RIGEL PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is -58%, being 101% points below the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 115,903 |
| Cost of Goods Sold | 1,749 |
| Intangible Assets | 0 |
| Liabilities, Current | 65,211 |
| Liabilities, Non-Current | 43,236 |
| Other Assets | 17,519 |
| Other Compr. Net Income | -51 |
| Other Expenses | 5,027 |
| Other Liabilities | 39,448 |
| Other Net Income | 684 |
| Other Revenues | 120,242 |
| Property and Equipment | 857 |
| Research and Development | 60,272 |
| Selling, General and Administrative Expense | 112,451 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 134,279 |
| Liabilities | 147,895 |
| Expenses | 179,499 |
| Revenues | 120,242 |
| Stockholders Equity | -13,616 |
| Net Income | -58,573 |
| Comprehensive Net Income | -58,598 |
| Economic Capital Ratio | -58% |